 Netscientific PLC said it was encouraged by the progress being made at PDS Biotech after the US portfolio company released second-quarter results yesterday. Ilian Iliev, NetScientifics CEO, added: We are pleased with the continued progress by PDS Biotech in its Phase 2 trials and broader corporate development, coming despite the ongoing volatility in the biotech public markets. 